STRO
SUTRO BIOPHARMA, INC.Company Information
- Company Name
- SUTRO BIOPHARMA, INC.
- CIK
- CIK0001382101
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- STRO: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- STRO
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-10-15
- Last sale
- 2024-01-29
- Shares purchased (TTM)
- 111,754
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 16,121,440
- Shares outstanding
- 16,571,602
- Ownership
- 97.28%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- -5.77%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 54 | 74 | 58 | 66 | 64 | 106 | 190 | 175 | 91 | 65 | 69 | 82 | ||||||
| Marketable Securities Current | 110 | 129 | 83 | 102 | 141 | 143 | 127 | 214 | 285 | 202 | 264 | 239 | ||||||
| Equity Securities Fv Ni | - | - | - | - | - | - | - | 0 | 50 | 46 | 42 | 34 | ||||||
| Accounts Receivable Net Current | 6 | 12 | 4 | 4 | 8 | 14 | 9 | 7 | 7 | 31 | 36 | 17 | ||||||
| Prepaid Expense And Other Assets Current | 6 | 6 | 6 | 11 | 19 | 25 | 18 | 11 | 11 | 10 | 10 | 9 | ||||||
| Assets Current | 176 | 221 | 151 | 182 | 232 | 287 | 343 | 406 | 443 | 355 | 422 | 381 | ||||||
| Property Plant And Equipment Net | 8 | 9 | 11 | 13 | 15 | 17 | 18 | 19 | 19 | 21 | 22 | 22 | ||||||
| Operating Lease Right Of Use Asset | 8 | 10 | 11 | 13 | 15 | 16 | 18 | 19 | 20 | 22 | 23 | 24 | ||||||
| Marketable Securities Noncurrent | 0 | 0 | - | - | - | - | - | - | - | 0 | - | - | ||||||
| Other Assets Noncurrent | 1 | 1 | 0 | 0 | 0 | 0 | 7 | 7 | 5 | 6 | 4 | 3 | ||||||
| Restricted Cash Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 194 | 242 | 174 | 210 | 262 | 321 | 387 | 452 | 489 | 403 | 471 | 432 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 3 | 5 | 8 | 7 | 4 | 8 | 10 | 6 | 6 | 8 | 9 | 6 | ||||||
| Accrued Liabilities Current | 6 | 5 | 15 | 13 | 12 | 12 | 13 | 13 | 10 | 7 | 15 | 11 | ||||||
| Contract With Customer Liability Current | 6 | 9 | 11 | 9 | 12 | 69 | 70 | 73 | 74 | 21 | 21 | 24 | ||||||
| Operating Lease Liability Current | 7 | 8 | 8 | 8 | 8 | 8 | 7 | 7 | 7 | 7 | 6 | 6 | ||||||
| Debt Current | - | - | - | - | - | - | - | - | - | - | 4 | 7 | ||||||
| Liabilities Current | 53 | 71 | 75 | 72 | 74 | 133 | 132 | 131 | 130 | 80 | 94 | 74 | ||||||
| Contract With Customer Liability Noncurrent | 0 | 1 | 2 | 4 | 7 | 9 | 13 | 18 | 22 | 46 | 53 | 78 | ||||||
| Operating Lease Liability Noncurrent | 4 | 6 | 8 | 10 | 12 | 14 | 16 | 18 | 20 | 21 | 23 | 25 | ||||||
| Long Term Debt Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Other Liabilities Noncurrent | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | - | ||||||
| Liabilities | 298 | 309 | 306 | 297 | 294 | 347 | 343 | 341 | 337 | 305 | 321 | 319 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 952 | 950 | 845 | 844 | 842 | 837 | 831 | 825 | 818 | 716 | 709 | 703 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | -0 | -0 | 0 | 0 | -0 | -0 | 0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -1,055 | -1,016 | -978 | -931 | -874 | -863 | -787 | -714 | -666 | -618 | -559 | -590 | ||||||
| Stockholders Equity | -103 | -67 | -132 | -87 | -32 | -26 | 45 | 111 | 152 | 98 | 150 | 112 | ||||||
| Liabilities And Stockholders Equity | 194 | 242 | 174 | 210 | 262 | 321 | 387 | 452 | 489 | 403 | 471 | 432 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | ||||||
| Common Stock Shares Issued | 17 | 17 | 9 | 9 | 8 | 8 | 8 | 8 | 8 | 6 | 6 | 6 | ||||||
| Shares Outstanding | 17 | 17 | 9 | 9 | 8 | 8 | 8 | 8 | 8 | 6 | 6 | 6 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialSUTRO BIOPHARMA, INC. (STRO) — SEC Financial Statements & Analysis
SUTRO BIOPHARMA, INC. (STRO) is a biological products, (no diagnostic substances) company. SUTRO BIOPHARMA, INC. trades on Nasdaq as: STRO. SUTRO BIOPHARMA, INC. (STRO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, SUTRO BIOPHARMA, INC. carries a market cap of $550.18M, a P/E ratio of -3.05x, a P/B ratio of -5.33x, a P/S ratio of 12.04x, an enterprise value of $495.84M, and an EV/EBITDA multiple of -3.54x. On profitability, it posts an operating margin of -319.57%, a net margin of -395.25%, a Return on Equity (ROE) of 266.76%, a Return on Assets (ROA) of -79.08%, and a Return on Invested Capital (ROIC) of -119.42%. Per share, it reports EPS of $-10.90, diluted EPS of $-10.90, free cash flow per share of $-8.76, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -56.25% year-over-year, net income growth of -13.45% year-over-year, and EPS growth of -55.54% year-over-year. On the balance sheet, it maintains a current ratio of 3.32x, a quick ratio of 3.22x, working capital of $122.75M, a debt-to-equity ratio of -2.88x, a debt ratio of 1.53, free cash flow of $-145.17M (TTM), and net debt of $-54.34M. Figures sourced from SEC EDGAR.
- Market Cap
- $550.18M
- P/E TTM
- -3.05x
- EPS TTM
- $-10.90
- P/B TTM
- -5.33x
- ROE TTM
- 266.76%
- ROA TTM
- -79.08%
- Debt To Equity
- -2.88x
- Free Cash Flow TTM
- $-145.17M
- Net Revenue TTM Growth 1Y
- -56.25%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is SUTRO BIOPHARMA, INC. in?
SUTRO BIOPHARMA, INC. (STRO) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does STRO trade on?
SUTRO BIOPHARMA, INC. (STRO) trades on the Nasdaq.
When was SUTRO BIOPHARMA, INC. (STRO)'s most recent SEC filing?
SUTRO BIOPHARMA, INC. (STRO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is STRO's market cap?
SUTRO BIOPHARMA, INC. (STRO) has a market capitalization of $550.18M as of 2026-06-30.
What is STRO's EPS (earnings per share)?
SUTRO BIOPHARMA, INC. (STRO)'s trailing twelve month EPS is $-10.90 as of 2026-06-30.
What is STRO's ROE (return on equity)?
SUTRO BIOPHARMA, INC. (STRO)'s trailing twelve month Return on Equity (ROE) is 266.76% as of 2026-06-30.
What is STRO's ROA (return on assets)?
SUTRO BIOPHARMA, INC. (STRO)'s trailing twelve month Return on Assets (ROA) is -79.08% as of 2026-06-30.
What is STRO's ROIC (return on invested capital)?
SUTRO BIOPHARMA, INC. (STRO)'s trailing twelve month Return on Invested Capital (ROIC) is -119.42% as of 2024-03-31.
What is STRO's EV/EBITDA?
SUTRO BIOPHARMA, INC. (STRO)'s trailing twelve month EV/EBITDA is -3.54x as of 2026-06-30.